NCT02623998 - Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita) | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

July 9, 2016

Primary Completion Date

September 1, 2018

Study Completion Date

November 30, 2019

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

insulin glargine

Dose is titrated to achieve fasting normoglycemia

DRUG

sitagliptin/metformin

Dose is titrated to 50/1000 mg bid or maximal tolerated dose

BEHAVIORAL

lifestyle therapy

Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving

Trial Locations (6)

T2T 5C7

University of Calgary, Calgary

R3E 3P4

Health Science Centre, Winnipeg

Unknown

McMaster University, Hamilton

LMC, Markham

Univeristy of Montreal, Montreal

N6A 4V2

St. Joseph's Hospital, London